Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amarin

- PMLiVE

NICE U-turn on Novartis’ Afinitor for kidney cancer

Set to back treatment's routine NHS use following offer of discount and new data

National Institute for Health and Care Excellence NICE logo

NICE recognises Smartinhaler as best practice for asthma care

Digital monitoring device proven to increase adherence and reduce hospital visits

- PMLiVE

Wales unveils ‘sensible’ £80m medicines access fund

New scheme hopes to provide greater consistency and accelerate availability by eight weeks

- PMLiVE

New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients

- PMLiVE

NICE green lights Keytruda for second-line lung cancer

Merck & Co's oncology treatment backed in draft guidance for NSCLC

- PMLiVE

NICE changes stance on GSK’s asthma drug Nucala

A newly-agreed price cut and additional cost-effectiveness data prompt U-turn

- PMLiVE

NICE U-turn sees Celgene’s Imnovid backed for multiple myeloma

New data and a discount swayed the cost-effectiveness body

- PMLiVE

Hey You! campaign targets over 60s at high risk of stroke

Bayer launches atrial fibrillation awareness drive starring rock and roll

Bristol-Myers Squibb (BMS) building

NICE backs BMS leukaemia drug Sprycel

Watchdog approves blood cancer therapy for use by NHS in England and Wales

Roche's Perjeta pertuzumab

NICE backs Roche’s Perjeta for routine NHS use

Set to become first new breast cancer drug in nine years after discount agreed

- PMLiVE

Amgen’s Repatha unclogs blocked arteries, says study

Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links